'Suicide' gene for the control of graft-versus-host disease

Current Opinion in Hematology

Volumn 5, Issue 6, 1998, Pages 478-482

  Tiberghien, Pierre ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; EPSTEIN BARR VIRUS; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX VIRUS 1; HUMAN; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE; T LYMPHOCYTE;

EID: 0031774797     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199811000-00021     Document Type: Article

References (31)

1. Graft-versus-host disease: Immunology, pathophysiology and treatment. Hematology, vol. 12. Edited by Burakoff SJ, Degg HJ, Ferrara J, Atkinson K. New York: Marcel Dekker; 1990.
2. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562
3. Antin JH: Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993, 82:2273-2277
4. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, Bekkum DWV, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130
5. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986, 314:729-735
6. Bowden RA: Infections in patients with graft-vs-host disease. In Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. Edited by Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K. Hematology/Volume 12. NewYork: Marcel Dekker; 1990:525
7. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D: Impairment of leukaemia-free survival by addition of interleukin-2 receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995, 345:1144-1146
8. Kolb HJ, Schattznberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman O, Ferrant A, Verdonck L, Niederwieser D. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995, 86:2041-2050
9. Tiberghien P: Use of suicide genes in gene therapy. J Leukocyte Biol 1994, 56:203-209
10. Borelli E, Heyman R, Hsi M, Evans RM: Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci U S A 1988, 85:7572-7576
11. Heyman RA, Borrelli E, Lesley J, Anderson D, Richman DD, Baird SM, Hyman R, Evans RM: Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci U S A 1989, 86:2698-2702
12. Papadopoulos EB, Ladanyi M, Emmanuel D, McKinnon S, Boulad F, Carabasi MH, Castro-Malaspina, Barrett VH, Gillio AP, Small TN, Young JW, Kernan N, O'Reilly RJ: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330:1185-1191
13. Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux JM, Contassot E, Murphy WJ, Lyons R, Chiang Y, Longo DL, Hervé P, Ruscetti FW: Ganciclovir treatment of herpes simplex kinase-transduced primary T-lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994, 84:1333-1341
14. Munschi NC, Govindarajin R, Ding LM, Iyer R, Saylors R, Kornbluth J, Marcus S, Chiang Y, Ennist D, Kwack L, Reynolds C, Tricot G, Barlogie B: Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997, 89:1334-1340
15. Contassot E, Deschaseaux M, Certoux JM, Reynolds CW, Keller JR, Ruscetti FW, Merle C, Chiang Y, Longo DL, Cahn JY, Hervé P, Tiberghien P: Retroviral-mediated transfer of herpes-simplex thymidine kinase (HS-tk) gene in alloreactive T-lymphocytes. Hum Gene Ther 1998, 9:73-80 Replacing polyclonal stimulation by allogeneic stimulation prior to retroviral-mediated transduction of HS-tk results in strongly alloreactive, ganciclovir-sensitive T cells. The alloreactive pattern of the transduced T cells suggests a preferential, but not restricted, transduction of the alloantigen specific T lymphocytes.
16. Springett GM, Moen RC, Anderson S, Blaese M, Frech Anderson W: Infection efficiency of T-lymphocytes with amphotropic retroviral vectors is cell cycle dependent. J Virol 1989, 63:3865-3869.
17. Gallot G, Hallet MM, Gaschet J, Moreau JF, Vivien R, Bonneville M, Milpied N, Vié H: Human HLA-specific T-cell clones with stable expression of a suicide gene: a possible tool to drive and control a graft-versus-host-graft-versus-leukemia reaction? Blood 1996, 88:1098-1103.
18. Salmon P, Boyer O, Lores P, Jami J, Klatzmann D: Characterization of an intronless CD4 minigene expressed in mature CD4 and CD8 T cells, but not expressed in immature thymocytes. J Immunol 1996, 156:1873-1879.
19. Cohen JL, Boyer O, Salomon B, Onclerq R, Charlotte F, Bruel S, Boisserie G, Klatzmann D: Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 1997, 89:4636-4645. Ganciclovir treatment, initiated at time of BMT in a murine model, can durably prevent the occurrence of GVHD induced by transgenic donor TkTC.
20. Helene M, Lake-Bullock V, Scott Bryson J, Darrell Jennings C, Kaplan AM: Inhibition of graft-versus-host disease: use of a T cell-controlled suicide gene. J Immunol 1997, 158:5079-5082. Similar to Cohen et al. (Blood 1997, 89:4636-4645), the authors demonstrate that early ganciclovir treatment can significantly inhibit GVHD induced by transgenic donor TkTC.
21. Tiberghien P, Cahn JY, Brion A, Deconinck E, Racadot E, Hervé P, Milpied N, Lioure B, Gluckman E, Bordigoni P, Jacob W, Chiang Y, Marcus S, Reynolds C, Longo D: Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. Hum Gene Ther 1997, 8:615-624.
22. Contassot E, Murphy W, Angonin R, Pavy JJ, Bittencourt M, Robinet E, Reynolds C, Cahn JY, Hervé P, Tiberghien P: In vivo alloreactive potential of ex vivo-expanded primary T-lymphocytes. Transplantation, 1998, 65:1365-1370.
23. Bordignon C, Bonini C, Verzeletti S, Nobili N, Maggioni D, Traversari C, Giavazzi R, Servida P, Zappone E, Benazzi E, Bernardi M, Porta F, Ferrari G, Mavilio F, Rossini S, Blaese RM, Candotti F: Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 1995, 6:813-819.
24. Link CJ, Burt RK, Trayno AE, Drobyski WR, Seregina T, Levy JP, Gordon L, Rosen ST, Burns WH, Camitta B, Casper J, Horowitz M, Juckett M, Lawton C, Margolis D, Pietryga D, Rowlings P, Taylor C, Furtado M, Stefka J, Gupta-Burt S, Kaiser H, Vesole DH: Adoptive immunotherapy for leukemia: donor lymphocytes transduced with herpes simplex thymidine kinase gene for remission induction. Hum Gene Ther 1998, 9:115-134.
25. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Rugieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997, 276:1719-1724. First clinical results involving the use HS-tk-expressing donor T cells after allogeneic BMT: no acute toxicity, persistent circulation of the ganciclovir-sensitive TkTC, GVL effect, ganciclovir-sensitive GVHD, possible immune response against a product of the transfered genes.
26. Mavilio F, Ferrari G, Rossini S, Nobili C, CC, Bordignon C: Peripheral blood lymphocytes as target cells or retroviral vector-mediated gene transfer. Blood 1994, 83:1988-1997.
27. Robinet, Certoux JM, Ferrand C, Maples PB, Hardwick A, Jacob W, Hervé P, Tiberghien P: A closed culture system for the ex vivo transduction and expansion of human T lymphocytes. J Hemother 1998, 3:205-215.
28. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Körbling M, Keatting M, Kantarjian H, Champlin R: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
29. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998, 91:756-763.
30. Warren EH, Greenberg PD, Riddell SR: Cytotoxic T-lymphocytes-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998, 91:2197-2207.
31. Riddell SR, Eliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Mansey SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD: T-cell mediated rejection of gene-modified HIV-specrtic cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996, 2:216-223.